Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

The deadline for Medicare+Choice renewals provided a convenient way for bill opponents to attack the private insurance approach. Louisiana Democrat Rep. John said: "Today the last Medicare+Choice HMO servicing the seventh district of Louisiana announced they are pulling out." Connecticut Democrat Rep. DeLauro reported a similar June 28 announcement: "Today I was notified by an insurance company that offers Medicare+Choice HMO coverage to seniors in Connecticut that they are no longer going to be able to offer them coverage." Rhode Island Democrat Rep. Weygand had the hottest news from the cutback front: "Just 45 minutes ago, Mr. Speaker, I received this letter from United HealthCare of Rhode Island that proved that very same point. They are pulling out of Bristol County, Rhode Island, and telling all of their subscribers they will no longer have coverage at the end of the year. This is what this plan will do for our seniors with regard to prescription drugs"

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts